There are now multiple in vitro studies that have reported that inhibition or genetic knock-down of TRPC6 significantly reduces cancer cell migration and proliferation [81], suggesting that TRPC6 inhibition may be beneficial both in terms of cardioprotection from doxorubicin and anti-tumor efficacy. The gene discussed is TRPC6; the disease is cancer.